

Lesinurad (sodium)

Catalog No: tcsc3478



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg



Specifications

CAS No:

1151516-14-1

Formula:

$C_{17}H_{13}BrN_3NaO_2S$

Pathway:

Membrane Transporter/Ion Channel

Target:

URAT1

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 26 mg/mL (61.00 mM)

Alternative Names:

RDEA-594 sodium

Observed Molecular Weight:

426.26


Product Description

Lesinurad sodium is a **URAT1** and **OAT** inhibitor, is determined to be a substrate for the kidney transporters **OAT1** and **OAT3** with K_m values of 0.85 and 2 μM , respectively.

IC₅₀ & Target: Km: 0.85 μM (OAT1), 2 μM (OAT3)^[1]

In Vitro: Lesinurad is a novel selective uric acid reabsorption inhibitor (SURI). Lesinurad is determined to be a substrate for the kidney transporters organic anion transporter (OAT1) and OAT3 with K_m values of 0.85 and 2 μM , respectively^[1]. Lesinurad (RDEA594) is a URAT1 and OAT inhibitor, which increases proximal renal tubule urate excretion^[2]. Lesinurad (RDEA594) is a potential uric acid lowering agent through inhibition of uric acid reuptake, and exhibits favorable p450 profiles, inhibits CYP2C9 and CYP2C8 with IC₅₀ of 14.4 μM and 16.2 μM , respectively. IC₅₀s of Lesinurad are all above 100 μM for CYP1A2, CYP2C19, and CYP2D6^[3].

In Vivo: Lesinurad (RDEA594) shows better pharmacokinetics than its pro-drug RDEA806. The 100 mg dose of Lesinurad exhibits a pharmacological effect in the range of that produced by 300 mg to 800 mg single doses of RDEA806^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!